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Abstract
Background: Honey has previously been shown to have wound healing and antimicrobial properties, but this is
dependent on the type of honey, geographical location and flower from which the final product is derived. We
tested the antimicrobial activity of a Chilean honey made by Apis mellifera (honeybee) originating from the Ulmo
tree (Eucryphia cordifolia), against selected strains of bacteria.
Methods: Ulmo 90 honey was compared with manuka UMF® 25+ (Comvita®) honey and a laboratory synthesised
(artificial) honey. An agar well diffusion assay and a 96 well minimum inhibitory concentration (MIC)
spectrophotometric-based assay were used to assess antimicrobial activity against five strains of methicillin-resistant
Staphylococcus aureus (MRSA), Escherichia coli and Pseudomonas aeruginosa.
Results: Initial screening with the agar diffusion assay demonstrated that Ulmo 90 honey had greater antibacterial
activity against all MRSA isolates tested than manuka honey and similar activity against E. coli and P. aeruginosa.
The MIC assay, showed that a lower MIC was observed with Ulmo 90 honey (3.1% - 6.3% v/v) than with manuka
honey (12.5% v/v) for all five MRSA isolates. For the E. coli and Pseudomonas strains equivalent MICs were observed
(12.5% v/v). The MIC for artificial honey was 50% v/v. The minimum bactericidal concentration for all isolates tested
for Ulmo 90 honey was identical to the MIC. Unlike manuka honey, Ulmo 90 honey activity is largely due to
hydrogen peroxide production.
Conclusions: Due to its high antimicrobial activity, Ulmo 90 may warrant further investigation as a possible
alternative therapy for wound healing.
Background
The use of honey as a traditional remedy for microbial
infections dates back to ancient times [1]. The difference
in antimicrobial potency among the different honeys can
be more than 100-fold, depending on its geographical,
seasonal and botanical source as well as through har-
vesting, processing and storage conditions [2]. The anti-
microbial activity of honey is attributed largely to
osmolarity, pH, hydrogen peroxide production and the
presence of other phytochemical components e.g.
methylglyoxal (MGO) [3]. In vivo, such activity may
occur due to a synergistic relationship between any of
these components rather than a single entity.
Manuka honey which originates from the manuka tree
(Leptospermum scoparium) is sold as a therapeutic agent
world wide. The presence of MGO in manuka honey con-
tributes to its uniqueness and has been termed the unique
manuka factor (UMF®). To date there are many publica-
tions reporting both in vitro and in vivo on the therapeutic
properties of manuka honey, which have confirmed its
activity against a wide range of medically important
bacteria including methicillin-resistant Staphylococcus
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topical agent to manage surgical site or wound infections
is increasingly acknowledged [6], other honeys need to be
assessed and evaluated. Newly identified honeys may have
advantages over or similarities with manuka honey due to
enhanced antimicrobial activity, local production (thus
availability), and/or greater selectivity against medically
important organisms [7].
In the current clinical environment, with the emer-
gence of multi-drug resistant strains of bacteria, poten-
tial therapeutic agents to aid their control and
eradication warrant investigation. Here we report an
initial in vitro evaluation of honey originating from the
Ulmo tree (Eucryphia cordifolia) native to Chile, com-
pared with manuka and a laboratory synthesised honey.
Methods
Bacterial Strains
The antibacterial properties of three honeys were tested
against seven bacterial isolates, i.e. three reference
strains, Escherichia coli ATCC 35218, Pseudomonas aer-
uginosa ATCC 27853 and MRSA ATCC 43300 and four
MRSA clinical isolates (two nasal, 01322 and 00745 and
two surgical site/wound isolates, 00791 and 28965, from
patients in an Irish hospital). The clinical isolates were
identified as MRSA by routine laboratory methods;
detection of staphylocoagulase and clumping factor (Sta-
phaurex Plus, Remel, U.K.), and oxacillin resistance [by
determining oxacillin minimum inhibitory concentra-
tions (MIC)] using the MIC Evaluators system (Oxoid,
U.K.).
Honey samples
Three honey specimens were used in this study. Manuka
honey with UMF® 25+ (Comvita®, New Zealand), Ulmo
90 honey (Rio San Pedro Ltd. Chile) and a laboratory
synthesised (artificial) honey. The Ulmo 90 honey speci-
men was produced from the Ulmo tree (Eucryphia cor-
difolia), a large evergreen shrub, part of the temperate
rain forests of southern Chile that flowers from the end
of January until March. It had been analysed previously
by Rio San Pedro Ltd. and 90% of the nectar source in
t h i sh o n e yc o m e sf r o mt h eU l m ot r e ew i t ho n l yv e r y
small proportions coming from other native Chilean
rainforest plants http://www.riosanpedro.net/our_uni-
que_ulmo_honey.html. The sample was a broad-based
representative sample taken from a homogenised batch
of 10 tonnes of 90% Ulmo honey, harvested between
24.03.08 and 04.04.08 and taken from various apiaries in
t h ea r e ao fL a g oR i ñ i h u e .T h es a m p l ew a sn o tg a m m a -
irradiated. Laboratory synthesised honey was prepared
by weighing and dissolving 3.0 g sucrose, 15 g maltose,
80.1 g fructose and 67 g glucose (all supplied by Sigma-
Aldrich, Ireland) in 34 ml sterile deionised water. The
solution was heated briefly to 56°C in a water bath to
aid dissolving. This formulation represents the four pre-
dominant sugars found in natural honey samples [8]. To
prevent photodegradation of glucose oxidase found in
honey, giving rise to hydrogen peroxide antimicrobial
activity and to prevent the loss of hydrogen peroxide
activity during analysis, all honey samples were stored at
room temperature in the dark prior to testing and
honey dilutions were prepared fresh daily prior to test-
ing. A serial double dilution of honey (Ulmo, manuka or
laboratory honey) was prepared aseptically for use in
both the agar well diffusion and MIC assay from 50% to
0.02% v/v in nutrient broth (Oxoid, Fannin, Ireland).
From the 50% (v/v) honey solution, 12 serial 1:1 dilu-
tions were made, resulting in final concentrations of;
50%, 25%, 12.5%, 6.3%, 3.1%, 1.6%, 0.8%, 0.4%, 0.2%,
0.1%, 0.04%, and 0.02%. Hereafter, these solutions are
referred to as ‘test honey’.
Well diffusion assay
A screening assay using well diffusion [9] was carried
out with some minor modifications. Nutrient agar plates
(Oxoid, U.K.) were inoculated by rubbing sterile cotton
swabs that were dipped into bacterial suspensions (over
night cultures grown at 37°C on nutrient agar and
adjusted to 0.5 McFarland in sterile saline) over the
entire surface of the plate. After inoculation 8.2 mm dia-
meter wells were cut into the surface of the agar using a
sterile cork borer. Eighty micro-litres of test honey, at
each of the concentrations stated above, were added to
each well. Plates were incubated at 37°C for 24 h. For
P. aeruginosa, plates were incubated at 30°C. A diffusion
control of methylene blue was used [10]. Zones of inhi-
bition were measured using a Vernier caliper (Draper).
The diameter of zones, including the diameter of the
well, was recorded. Each assay was carried out in
triplicate.
Spectrophotometric assay for MIC determination
A previously described spectrophotometric assay for
MIC determination [10] was performed. Minimum inhi-
bitory concentrations were determined in sterile 96 well
round bottomed polystyrene microtitre plates (Corning
c o s t a rL t d . ,N Y ) .T e nμl of 0.5 McFarland standardised
culture (prepared as described above) was added to 190
μl of test honey, at each of the concentrations stated
above, in each well (six replicates per dilution, 12 dilu-
tions tested). Control wells contained broth only (nega-
tive or sterility control) or bacteria and broth (positive
control). Plates were incubated in the dark at 37°C with
shaking at 150 rpm for 24 h. Data were analysed accord-
ing to Patton et al., 2005 [10]. Briefly, the optical density
was determined just prior to incubation (T0) and again
after 24 h incubation (T24) at 600 nm. The OD for each
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replicate at T24. The adjusted OD of each control well
was then assigned a value of 100% growth. The percent
inhibition of growth was thus determined using the for-
mula Percent Inhibition = 1- (OD test well/OD of corre-
sponding control well) × 100. The MIC is reported as
the lowest concentration of test material which results
in 100% inhibition of growth of the test organism.
To establish if the antibacterial activity of the three
honey samples was bacteriostatic or bactericidal [11], 10
μl from a well with each concentration of honey where
bacterial growth was inhibited, were plated on to
Colombia Blood Agar (CBA) (Oxoid) and incubated
overnight. Plates with visible colony growth were con-
sidered to correspond to bacteriostatic honey activity
while those with no growth were recorded as represent-
ing bactericidal honey activity.
Hydrogen peroxide activity of honey
In order to determine if each of the honeys (Ulmo 90 and
manuka) had non-peroxide antimicrobial activity, honey
dilutions (50% - 1.6% v/v) were prepared in nutrient broth
containing catalase (Sigma, C-40) at a final concentration
of 0.2% w/v [12]. The assay was then conducted similar to
the MIC determination above, using the spectrophoto-
metric assay, with the exception that only MRSA isolate
0791 was used. Ten μl of 0.5 McFarland standardised cul-
ture of MRSA isolate 0791 was added to 190 μlo ft e s t
honey in each well (five replicates per dilution). Control
wells received broth and catalase only (negative or sterility
control) or bacteria and broth and catalase (positive con-
trol). Plates were incubated in the dark at 37°C at 150 rpm
for 24 h. After 24 h incubation, 10 μlf r o me a c hw e l lw a s
inoculated on to a CBA plate. Plates were incubated at 37°
C for 24 h and subsequently examined for growth.
Results
Initial screening with the agar diffusion assay demon-
strated that Ulmo 90 honey had superior antibacterial
activity against all isolates compared with manuka
honey. Table 1 outlines the antibacterial activity based
on the zone of clearing that was produced. Ulmo 90
honey produces a large or equivalent antibacterial effect
than manuka honey for each dilution when tested
against the five MRSA isolates. In addition at lower con-
centrations, Ulmo honey continued to have an antibac-
terial effect for three of the five MRSA isolates.
Comparable results against E. coli and P. aeruginosa
were observed.
The MIC plate assay, a more sensitive measure of
antimicrobial activity [10], showed that growth of all
seven isolates was largely inhibited by both manuka
honey and Ulmo 90 honey in comparison to the labora-
tory synthesised honey (Table 2). A lower MIC was
observed for Ulmo 90 honey (3.1%-6.3% v/v) in compar-
ison to manuka honey (12.5% v/v) for all five MRSA
strains. Equivalent MICs were found for E. coli and P.
aeruginosa for both honey types (12.5% v/v). The MIC
for the laboratory synthesised honey for all strains was
50% v/v. The MIC for Ulmo 90 honey was also the
minimum bactericidal concentration (MBC) for all iso-
lates tested, with the exception of MRSA 01322 and
0745). For manuka and the laboratory honey the MBC
was equivalent to the MIC.
The removal of hydrogen peroxide activity from Ulmo
90 honey reduced its antimicrobial activity. A 25% v/v
solution of the Ulmo 90 had no detectable antibacterial
activity when tested in the presence of catalase. In con-
trast, a 25% v/v solution of manuka maintained its anti-
bacterial activity in the presence of catalase/absence of
hydrogen peroxide.
Discussion
The in vitro antibacterial activity of Ulmo 90 and man-
uka honey was evaluated and compared. Data obtained
from the agar diffusion and spectrometric assays has
demonstrated, for the first time, that Ulmo 90 honey
exhibits a stronger peroxide attributable antimicrobial
Table 1 Mean Zones of Inhibition (diameter mm including well (8.2 mm))
Concentration 50% v/v 25% v/v 12.5% v/v 6.3% v/v
Isolates Ulmo Manuka Ulmo Manuka Ulmo Manuka Ulmo Manuka
MRSA ATCC 43300 30 (1.7) 24 (1.5) 26 (0.6) 19 (2.1) 18 (0.6) 13 (1.0) 10 (0.6) -
MRSA 0791* 34 (1.5) 23 (1.2) 29 (1.7) 17 (1.7) 22 (2.1) - 14 (2.5) -
MRSA 28965* 24 (1.0) 17 (1.7) 19 (1.5) 15 (2.0) ----
MRSA 01322* 28 (5.8) 22 (1.0) 23 (4.2) 18 (0.6) 17 (2.9) - 11 (2.0) -
MRSA 0745* 23 (2.7) 20 (1.7) 19 (2.1) 13 (1.7) 11 (2.7) - - -
P. aeruginosa ATCC 27853 14 (2.3) 16 (7.8) 11 (1.0) 14 (6.9) ----
E. coli ATCC 35218 14 (1.5) 15 (2.5) 11 (1.7) 12 (2.9) ----
* Clinical isolates
The antimicrobial activity of Ulmo honey in comparison to manuka honey against five MRSA strains, E. coli and Pseudomonas aeruginosa, assessed by agar well
diffusion assay (n = 3). Where no value is given, no zone of inhibition was observed.
Standard deviation values (±) are in brackets
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compared with manuka honey. Using the agar diffusion
method, on average, Ulmo honey displayed larger zones
of inhibition against all MRSA strains. However, in
some cases, large standard deviations were observed
(Table 1). This may be accounted for by the method
used to inoculate the bacteria on to the surface of the
agar. Although this method has been used in previous
studies [10], a more precise method may be to seed the
agar with the test organism as described by Allen et al.
(1991) [12].
A lower MIC was observed for Ulmo 90 honey (3.1% -
6.3% v/v) in comparison to manuka (12.5% v/v) for all
five MRSA strains. Although this difference, which is
one dilution, may not be significant. A previous report
[13], showed that the MBC from Medihoney (contains
manuka honey) against MRSA was 3% while ours was
3.1% v/v for Ulmo 90 for 3 of the 5 strains and 6.3% v/v
for the other two. That previous report [13] proposed
that there are differences in the susceptibility of strains
of the same species, which we have confirmed for
MRSA isolates. The MIC values for manuka honey may
seem high (12.5%), especially when compared to Patton
et al. (2006) [10], where the same spectrophotometric
assay was used. That study used a less potent manuka
honey (UMF 18+) with a resulting MIC of 6.25% v/v.
However, the differences observed between that study
and the current study may explain this anomaly, e.g. a
different strain of S. aureus was used in that study.
The removal of hydrogen peroxide activity from Ulmo
90 was shown to have reduced its antimicrobial activity.
A 25% v/v solution of the Ulmo 90 had no detectable
antibacterial activity when tested in the presence of cat-
alase, where previously a 3.1% v/v solution of Ulmo
honey was both the MIC and MBC for MRSA strain
0791. This would suggest that bacterial inhibition in the
previous experiments was mainly due to hydrogen
peroxide generation. Although some activity was
observed in Ulmo 90 at 50% v/v concentration, the
same activity was seen in the laboratory synthesised
honey, which may indicate that activity at this concen-
tration may be due to other factors such as osmotic
pressure or high sugar content. In contrast, while the
MIC and MBC was affected, a 25% v/v solution of man-
uka displayed antibacterial activity in the presence of
catalase i.e. this was the dilution at which both MIC and
MBC was observed on the removal of peroxide activity.
This finding was expected for manuka as it has been
previously shown that its antibacterial activity is attribu-
ted to non-peroxide components such as MGO [12]. As
catalase is present in body tissues, this may have an
effect on the in vivo activity of hydrogen peroxide-
dependent honeys. However the extent of this effect is
not known.
Similar to other studies, this paper presents the find-
ings of in vitro antibacterial activity of a honey against
planktonic bacteria and therefore results cannot be
extrapolated to the chronic wound environment. The
chronic wound harbours up to four different wound
pathogens [14] and indeed the presence of bacterial
wound biofilms compound the difficulties in under-
standing and managing such an environment [13].
Within the biofilm, the characteristics of the bacteria
change, so that biofilm-embedded bacteria are up to
1000 times more resistant to antibiotics than the ‘plank-
tonic’ bacteria that are used to test antibiotic sensitivity
[15]. The antibacterial nature of honey is dependent on
various factors working either singularly or synergisti-
cally, the most salient of which are; hydrogen peroxide
(produced by the glucose oxidase added to honey by
bees), phenolic compounds, wound pH, pH of honey;
osmotic pressure exerted by the honey, cleansing of the
wound bed by the honey, level of exudate and the fre-
quency of application. The degree to which any one of
these contribute to in vivo antimicrobial efficacy has yet
to be determined. However, a recent study examining
the antimicrobial properties of honey in vitro found that
hydrogen peroxide, MGO and an antimicrobial peptide,
bee defensin-1, were distinct mechanisms involved in
the bactericidal activity of honey [16]. In addition to its
antimicrobial properties, the effects of honey on host
cells may also play an important role in wound healing
[17,18]. Therefore to focus solely on peroxide in honey
limits our understanding of how honey may contribute
to managing the bacterial wound bioburden.
Conclusion
From the results contained in this report we conclude
that, due to its high antimicrobial activity, Ulmo 90 may
warrant further investigation into its use as a possible
alternative therapy for wound healing.
Table 2 Minimum inhibitory concentration (MIC) and
minimum bactericidal concentration (MBC) of Ulmo,
manuka and laboratory synthesised honey necessary to
inhibit 100% of the microbial growth in vitro expressed
in % v/v solution (n = 3)
Isolate Ulmo Manuka Laboratory
MIC MBC MIC MBC MIC & MBC
MRSA ATCC 43300 6.3 6.3 12.5 12.5 50
MRSA 0791* 3.1 3.1 12.5 12.5 50
MRSA 28965* 6.3 6.3 12.5 12.5 50
MRSA 01322 * 3.1 6.3 12.5 12.5 50
MRSA 0745* 3.1 6.3 12.5 12.5 50
P. aeruginosa ATCC 27853 12.5 12.5 12.5 12.5 50
E. coli ATCC 35218 12.5 12.5 12.5 12.5 50
* Clinical isolates
Values are modal values and expressed as a percentage of undiluted honey.
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